Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors

被引：0
|
作者：
Li, C.
Alvey, C.
Bello, A.
Wilner, K. D.
Tan, W.
机构：
[1] Pfizer Inc, San Diego, CA USA
[2] Pfizer Inc, New London, CT USA
[3] Pfizer Inc, New York, NY USA
[4] Pfizer Oncol, San Diego, CA USA
[5] Pfizer Inc, Pfizer Oncol Business Unit, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13065
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066), IN ALK-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Camidge, D. R.
    Bang, Y.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Solomon, B.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
  • [2] Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)
    Solomon, B.
    Bang, Y. J.
    Camidge, D. R.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
  • [3] PHASE 2 DATA FOR CRIZOTINIB (PF-02341066) IN ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PROFILE 1005
    Riely, Gregory J.
    Kim, Dong-Wan
    Crino, Lucio
    Janne, Pasi A.
    Blackhall, Fiona H.
    Camidge, David R.
    Hirsh, Vera
    Mok, Tony S. K.
    Solomon, Ben
    Soria, Jean-Charles
    Park, Keunchil
    Gadgeel, Shirish M.
    Martins, Renato G.
    Han, Ji-Youn
    De Pas, Tommaso
    Bottomley, Andrew
    Polli, Anna
    Petersen, Jennifer A.
    Tassell, Vanessa R.
    Shaw, Alice T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S411 - S412
  • [4] Effect of PF-02341066 and radiation on non-small cell lung cancer cells
    Tumati, Vasu
    Kumar, Subashri
    Yu, Lan
    Chen, Benjamin
    Choy, Hak
    Saha, Debabrata
    [J]. ONCOLOGY REPORTS, 2013, 29 (03) : 1094 - 1100
  • [5] Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
    Camidge, D. R.
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Wilner, K. D.
    Costa, D. B.
    Shapiro, G.
    LoRusso, P.
    Stephenson, P.
    Tang, Y.
    Ruffner, K.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Camidge, D. R.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [7] MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
    Tanizaki, Junko
    Okamoto, Isamu
    Okamoto, Kunio
    Takezawa, Ken
    Kuwata, Kiyoko
    Yamaguchi, Haruka
    Nakagawa, Kazuhiko
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (10) : 1624 - 1631
  • [8] Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Papachristos, A.
    Masinde, S.
    Davis, J. D.
    Gullo, G.
    Rietschel, P.
    Paccaly, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S308 - S309
  • [9] PHARMACOKINETICS (PK) OF CRIZOTINIB (PF-02341066), A DUAL ALK/C-MET INHIBITOR, FOLLOWING ADMINISTRATION OF MULTIPLE ORAL DOSES TO PATIENTS WITH ADVANCED ALK-POSITIVE NSCLC IN CHINA
    Tan, Weiwei
    O'Gorman, Melissa
    Lanzalone, S.
    Wilner, Keith
    Boyd, Jason
    Liu, Xiaoquing
    Wu, Yi-long
    Qin, Shukui
    Han, Baohui
    Shi, Yuankai
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S491 - S491
  • [10] Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.
    Tan, W.
    Wilner, K. D.
    Bang, Y.
    Kwak, E. L.
    Maki, R. G.
    Camidge, D. R.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345